Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...

Trodelvy reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The median progression-free survival ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer harboring one or ...

Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall ...

Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ...